Codix Group, a subsidiary of Colexa Biosensor Ltd, has been approval by the World Health Organisation, WHO, to commence the packaging of a WHO Prequalified Rapid Diagnostic Test kit at its factory in Nigeria. With this development the Colexa Biosensor is now allowed to locally package the WHO Prequalified HIV Rapid Diagnostic Test in the country and distribute.
The development was released through a statement by the Codix Group this morning saying the milestone positions achieved in Nigeria will now position the country as a key player in advancing healthcare production capabilities and improving access to life-saving diagnostics.
The statement partly reads; “The Standard Q HIV 1/2 Ab 3-Line Test is now the first WHO Prequalified HIV RDT approved for packaging within Africa, marking a historic feat for the continent.”
It added that the achievement has reflected the company’s dedication to strengthening Nigeria’s healthcare infrastructure and aligning with the President Tinubu Renewed Hope Agenda vision to enhance local manufacturing and innovation.
The statement continued, “Since it’s commissioning in December 2023, Colexa Biosensor has earned recognition from global health organizations, including WHO, Global Fund, UNITAID, FIND, and PEPFAR. The factory’s operational capacity represents a significant step toward reducing dependence on imports, improving access to high-quality In-Vitro Diagnostics (IVDs), and fostering Nigeria’s healthcare value chain.
“This approval also paves the way for procurement opportunities by Nigeria and international donors, further boosting local and global efforts to combat HIV. Codix Group expressed its pride in achieving this milestone and reaffirmed its commitment to elevating healthcare standards across the nation and beyond.”
Meanwhile, it is expected that the achievement will inspire further investment in the health sector production in Nigeria which will benefit Africa at large.
